NIKKEI 225
37,660.35 +31.87 (+0.08%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.87 +0.30 (+0.36%) GOLD FUTURES
2,341.20 -1.30 (-0.06%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,414.56 -199.33 (-0.39%)
Vapotherm, Inc. (VAPO)
| Previous close | 1.2660 |
| Open | 1.2600 |
| Bid | 0.0000 x 1300 |
| Ask | 0.0000 x 800 |
| Day's range | 1.2500 - 1.2600 |
| 52-week range | 0.7500 - 7.4400 |
| Volume | |
| Avg. volume | 8,706 |
| Market cap | 7.841M |
| Beta (5Y monthly) | -1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.5700 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.00 |
PR NewswireOnymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
Onymos, developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. This partnership will help Vapotherm create a unique respiratory digital platform to meet its data visualization and device management goals for th
PR NewswireVapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
- PR Newswire
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced that David Yamane, MD was awarded the Star Research Award by the Society for Critical Care Medicine (SCCM) at the 2024 Critical Care Congress. The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.
